Harrington Discovery Institute at University Hospitals Opens Call for Harrington Rare Disease Scholar Award

Cleveland, Ohio, USA – May 24, 2017 – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its request for proposals for the Harrington Rare Disease Scholar Award. The Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases. The program is sponsored by Takeda Pharmaceutical Company Limited (TSE: 4502) and overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines.

“We are excited to launch this new program with Takeda,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The Harrington Rare Disease Scholar Award provides a unique opportunity to advance cutting-edge research in rare diseases into life-saving treatments.”

Harrington Rare Disease Scholars will receive:

- **Financial support** of $150,000 guaranteed
- Eligibility for additional funding up to $1,000,000
- **Drug development and project management support** through Harrington Discovery Institute’s [Innovation Support Center](#)
- Facilitated access to Takeda’s research and development experts

Letters of Intent are being accepted through **July 19, 2017**.

All applications must be submitted online at [HarringtonDiscovery.SmartSimple.com](http://HarringtonDiscovery.SmartSimple.com).

Harrington Discovery Institute will select up to 10 researchers to receive the Harrington Rare Disease Scholar Award. Scholars will work closely with drug development experts from its Innovation Support Center, which provides hands-on industry guidance not found in traditional academic research settings. **Harrington Rare Disease Scholars and their institutions retain the intellectual property rights to their work.**

The award is open to MD and PhD researchers at accredited academic medical centers, research institutions, and universities in the United States. Selection criteria include innovation, creativity and potential for impact on human health. Award recipients will be selected by Harrington Discovery Institute’s Scientific Advisory Board for Rare Diseases and announced in early 2018.

# # #
**Harrington Discovery Institute**
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive physician-scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

**The Harrington Project for Discovery & Development**
The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discoveries into medicines for benefit of society.

For more information about The Harrington Project and Harrington Discovery Institute, visit: HarringtonDiscovery.org.

**About University Hospitals**
Founded in 1866, University Hospitals serves the needs of over 1 million patients per year through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children’s hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, dermatology, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is the second largest employer in northern Ohio with 26,000 employees. For more information, go to UHhospitals.org.

**Harrington Discovery Institute Contact:**
Natalie Haynes – USA
natalie.haynes@harringtondiscovery.org
+1-216-368-1038